MIAMI, May 12, 2026, 19:03 EDT
- OpenEvidence is teaming up with the Society of Surgical Oncology to bring SSO clinical content onto its AI platform.
- The group is also putting up a $100,000 grant over 24 months for surgeon-led projects focused on new technologies.
- OpenEvidence shifted its base from Cambridge, Massachusetts, to Miami, landing this deal after a string of quick clinical-content partnerships.
OpenEvidence has teamed up with the Society of Surgical Oncology, moving to integrate the group’s surgical cancer-care resources into its medical AI platform. The deal also includes a $100,000 grant earmarked for surgeon-led research, a fresh step as the company extends its reach into specialty medicine.
The agreement takes on new significance as AI shifts from test runs to a regular part of doctors’ work. In March, the American Medical Association reported 81% of physicians surveyed now use AI on the job—over twice the percentage from 2023. Top tasks include medical research summaries and handling documentation.
This also throws new light on OpenEvidence’s departure from Massachusetts. Although the company started out in Cambridge, by October—when it secured its $200 million raise—it was already headquartered in Miami, according to the Boston Globe. Founder and CEO Daniel Nadler confirmed the relocation but declined to give a reason.
The SSO partnership brings the society’s clinical content and educational tools straight into OpenEvidence, right next to peer-reviewed studies and citations. “So many of our members were already using OpenEvidence,” SSO President Kenneth Tanabe said. Business Wire
SSO says the grant will roll out this summer; a recipient should be named in the fall. The focus: AI-powered medical knowledge and clinical decision support—tools designed to help clinicians sift through evidence, follow guidelines, and navigate care choices during patient treatment.
OpenEvidence has been ramping up its efforts in oncology. In late April, the company announced it had added National Comprehensive Cancer Network oncology treatment algorithms to its platform, pairing answers with direct links to NCCN source materials. Chief Medical Officer Travis Zack described the NCCN guidelines as “central” to his approach to patient care. Business Wire
OpenEvidence is pushing past its roots in question-and-answer search. In March, the company launched Coding Intelligence to handle some of the grunt work in medical billing, according to Modern Healthcare. That comes on the heels of last year’s rollout of OpenEvidence Visits, a tool for generating clinical notes.
That expansion comes with a hefty price tag. OpenEvidence pulled in $250 million back in January, valuing the company at $12 billion—twice what it was worth just three months earlier. Thrive Capital and DST Global led the financing, according to the company.
Competition is heating up. Wolters Kluwer’s UpToDate, a staple among doctors, has jumped into generative AI. Doximity’s also upping its game, expanding its AI reach with Pathway—the clinical AI outfit it bought, as STAT reported last year.
Trust stands out as the big risk. While doctors seem eager for quicker evidence, the AMA points out that most want robust validation, privacy protections, and well-defined liability rules in place before they’ll fully back AI. There’s also worry about trainees losing hands-on skills.
OpenEvidence says it pulls its answers directly from medical literature, not the open web. Speaking with Fierce Healthcare back in January, Nadler said most of the firm’s budget is earmarked for model training and compute expenses.
The SSO announcement lands as another health-care AI highlight for Miami’s relocated company. Surgeons, though, face a more immediate question: can the platform stay current with rapidly shifting cancer guidelines, and do so without piling on extra work for clinicians?
